Servier & Miragen Ink $352M Partnership Deal

Under the partnership, the two companies will advance the research, development and commercialization of three drug candidates.

European pharmaceutical company Les Laboratoires Servier and preclinical-stage biopharmaceutical company Miragen Therapeutics, Inc. announced Tuesday an agreement for advancing the research, development and commercialization of three drug candidates.

The agreement includes two of miRagen's lead programs (miR-208 and miR-15/195) and one additional target yet to be identified, for cardiovascular disease. This partnership provides worldwide rights, excluding the U.S. and Japan, to Servier.

Under the terms of the agreement, Miragen will receive up to $45 million in total upfront, research support and near-term milestone payments over the next three years, as well as royalties on sales, based on the successful outcome of the collaboration. Additional clinical